Literature DB >> 667729

Dantrolene blocks intracellular calcium release in smooth muscle: competitive antagonism of thromboxane A2.

A I Ally, D F Horrobin, M S Manku, R O Morgan, M Karmazyn, R A Karmali, S C Cunnane.   

Abstract

Dantrolene sodium has been shown to block the release of intracellular calcium in skeletal muscle. It has been proposed that dantrolene blocks the movement and (or) action of a natural calcium ionophore. In a rat vascular preparation dantrolene was found to inhibit pressor responses to noradrenaline and angiotensin but not those to potassium with an IC50 concentration within the therapeutic levels in man. Imidazole, an inhibitor of thromboxane A2 (TXA2) synthesis, had similar actions to dantrolene. Interactions between imidazole and dantrolene suggested that dantrolene may be a competitive antagonist of TXA2 in muscle. We report the first demonstration of an effect of dantrolene sodium on smooth muscle contractility and suggest that TXA2 is an essential modulator of vascular reactivity. A similar role has been shown for TXA2 in platelets.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667729     DOI: 10.1139/y78-080

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  5 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

2.  Interaction of atriopeptin III and vasopressin on calcium kinetics and contraction of aortic smooth muscle cells.

Authors:  H Meyer-Lehnert; C Caramelo; P Tsai; R W Schrier
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

3.  Postoperative Malignant Hyperthermia- A Medical Emergency: A Case Report and Review of Literature.

Authors:  Amit Kumar Sinha; Poonam Kumari; Maheshkumar Manilal Vaghela; Chandni Sinha; Bindey Kumar
Journal:  J Clin Diagn Res       Date:  2017-04-01

Review 4.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 5.  The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.

Authors:  Saadet Inan; Huafeng Wei
Journal:  Anesth Analg       Date:  2010-09-22       Impact factor: 6.627

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.